GlassScriptPhysician profile
Christopher D Allee
NPI 1154324408
$7,602.19
in general payments reported to CMS, 2019-2025
32 companies · $864 in 2025
The $864 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $1,102 · 2021: $1,205 · 2022: $1,190 · 2023: $1,124 · 2024: $910 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,194.70 | 2019-2025 | Cequa |
| Abbvie INC. | $1,018.55 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $777.09 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Allergan, INC. | $608.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $563.61 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $358.75 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $322.89 | 2019-2022 | |
| Optos, INC. | $284.96 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $284.51 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Shire North American Group INC | $235.18 | 2019 | |
| Kala Pharmaceuticals, INC. | $206.90 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $188.67 | 2019-2021 | |
| Harrow Eye, LLC | $168.83 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $133.40 | 2022-2023 | Tearcare System |
| Rxsight INC | $132.08 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $126.78 | 2022-2024 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $110.54 | 2023-2025 | Iyuzeh |
| Quidel Corporation | $97.55 | 2019 | |
| Genzyme Corporation | $94.87 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $94.69 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.77 | 2019-2021 | |
| Dompe US, INC. | $79.81 | 2022-2025 | Oxervate |
| Glaukos Corporation | $79.41 | 2021-2024 | Idose |
| New World Medical,INC. | $71.65 | 2019-2022 | |
| Biotissue Holdings INC. | $70.53 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $48.86 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $47.72 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $46.55 | 2023 | Iolmaster 700 |
| Regeneron Healthcare Solutions, INC. | $23.02 | 2021 | |
| Horizon Therapeutics Plc | $16.46 | 2023 | Tepezza |
| Omeros Corporation | $14.50 | 2020 | |
| Lumenis, INC | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Allee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.